Objective The objective is to summarize the knowledge on the epidemiology,
pathophysiology and management of secondary headache attributed to SARS-CoV-2 …

Determinants of protective immunity against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection require the development of well-standardized, reproducible …

In the current COVID‐19 pandemic, a better understanding of the relationship between
merely binding and functionally neutralizing antibodies is necessary to characterize …

Severe COVID-19 is linked to both dysfunctional immune response and unrestrained
immunopathology, and it remains unclear whether T cells contribute to disease pathology …

The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly
developed mRNA vaccines can prevent the spread of the virus. Headache is the most …

It is not clear whether there is an association between adverse reactions and immune
response after vaccination. Seven hundred and thirty-five vaccinees from our University …

The plaque reduction neutralization test (PRNT) is a preferred method for the detection of
functional, SARS-CoV-2 specific neutralizing antibodies from serum samples. Alternatively …

Introduction The most frequently reported neurological adverse event of ChAdOx1 nCoV-19
(AZD1222) vaccine is headache in 57.5%. Several cases of cerebral venous thrombosis …

Morbidity and mortality of COVID-19 is increased in patients with inborn errors of immunity
(IEI). Age and comorbidities and also impaired type I interferon immunity were identified as …

ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has now caused over 2 million …